BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
0 hedge funds and large institutions have $0 invested in BRAINSTORM CELL THERAPUTC in 2025 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 5 closing their positions.
0.02% less ownership
Funds ownership: 0.02% → 0% (-0.02%)
100% less funds holding
Funds holding: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $1.73K → $0 (-$1.73K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Osaic Holdings
Scottsdale,
Arizona
| – | -$1.35K | -1,785 | Closed |
|
|
BSB
2
Bangor Savings Bank
Bangor,
Maine
| – | -$188 | -266 | Closed |
|
|
VWA
3
VSM Wealth Advisory
Hunt Valley,
Maryland
| – | -$85 | -120 | Closed |
|
|
SPIA
4
Steward Partners Investment Advisory
New York
| – | -$80 | -113 | Closed |
|
|
DJSG
5
D.J. St. Germain
Springfield,
Massachusetts
| – | -$23 | -33 | Closed |
|
BCLI Hedge Fund Activity: Q4 2025 in Review
0 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2025, worth a combined $0 — down 100% from $1.73K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BCLI and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Osaic Holdings, exiting entirely with an estimated $1.35K sold.
- 0 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2025, down from 5 in Q3 2025.
- Funds reported $0 of BRAINSTORM CELL THERAPUTC stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2025 and 5 closed out, a net change of -5 holders.
- The largest BRAINSTORM CELL THERAPUTC seller in Q4 2025 was Osaic Holdings, an estimated $1.35K sold.
Based on aggregated 13F filings for Q4 2025.